AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6684935 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide 25 mg
Number of subjects: 0
Study 30714500 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochlear™ Nucleus® 7 Sound Processor (SP)
Number of subjects: 37
Study 30714500 — intervention group
Group type: COMPARATOR
Intervention: Direct wireless streaming from an Apple® smartphone to the SP
Number of subjects: 37
Study 30714500 — intervention group
Group type: COMPARATOR
Intervention: Previous generation SP
Number of subjects: 37
Study 29524664 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavity shave margins excision or re-excision of positive margins; specific details on dosage and duration not available.
Number of subjects: 235
Study 29524664 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger patient age (under 60 years); specific details on dosage and duration not available.
Number of subjects: 235
Study 29524664 — intervention group
Group type: EXPERIMENTAL
Intervention: High-grade ductal carcinoma in situ; specific details on dosage and duration not available.
Number of subjects: 235
Study 27565996 — intervention group
Group type: EXPERIMENTAL
Intervention: Briefing on the recommendations for an unexpected difficult airway prior to induction of anaesthesia
Number of subjects: 19
Study 27565996 — intervention group
Group type: COMPARATOR
Intervention: Web-based cognitive aid with an emergency manual page containing the identical algorithm
Number of subjects: 19
Study 24406256 — intervention group
Group type: EXPERIMENTAL
Intervention: Organo-silane product 1
Number of subjects: 9
Study 24406256 — intervention group
Group type: EXPERIMENTAL
Intervention: Organo-silane product 2
Number of subjects: 9
Study 24406256 — intervention group
Group type: COMPARATOR
Intervention: Quaternary ammonium disinfectant
Number of subjects: 9
Study 21564271 — intervention group
Group type: EXPERIMENTAL
Intervention: ST(2), wax solvent (Dewaks, Faber Kimya & Ilaç, Turkey)
Number of subjects: 120
Study 21564271 — intervention group
Group type: EXPERIMENTAL
Intervention: ST(3), boiling water followed by conditioning with methyl methacrylate (MMA) monomer (Meliodent, Bayer Dental, Germany)
Number of subjects: 120
Study 21564271 — intervention group
Group type: EXPERIMENTAL
Intervention: ST(4), boiling water followed by wax solvent agent and finally MMA monomer application
Number of subjects: 120
Study 21564271 — intervention group
Group type: COMPARATOR
Intervention: ST(1), no treatment applied (control)
Number of subjects: 120
Study 19653481 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence accumulation model for conflict detection performance
Number of subjects: 0
Study 19653481 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence accumulation models
Number of subjects: 0
Study 17257471 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 440
Study 17257471 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 440
Study 17257471 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of comorbid substance abuse
Number of subjects: 440
Study 17257471 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive relationship with clinical staff (ROMI item)
Number of subjects: 440
Study 17257471 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulfillment of life goals (ROMI item)
Number of subjects: 440
Study 15069045 — intervention group
Group type: COMPARATOR
Intervention: 21 or more ejaculations per month
Number of subjects: 29342
Study 15069045 — intervention group
Group type: COMPARATOR
Intervention: High ejaculation frequency
Number of subjects: 29342
Study 15069045 — intervention group
Group type: EXPERIMENTAL
Intervention: Ejaculation frequency
Number of subjects: 29342
Study 12472855 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilization flat occlusal splint for night use (n = 21)
Number of subjects: 37
Study 12472855 — intervention group
Group type: COMPARATOR
Intervention: No splint (n = 16)
Number of subjects: 37
Study 9799978 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalational anaesthesia without prophylactic antiemetic treatment
Number of subjects: 2220
Study 9799978 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalational anaesthesia
Number of subjects: 2220
Study 7813605 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous injection of 6 mg benperidol (BPD)
Number of subjects: 12
Study 7813605 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral liquid application of 6 mg benperidol (BPD)
Number of subjects: 12
Study 7813605 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tablet application of 6 mg benperidol (BPD)
Number of subjects: 12
Study 7813605 — intervention group
Group type: EXPERIMENTAL
Intervention: All applications of BPD (i.v., liquid, tablets)
Number of subjects: 12
Study 7813605 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute doses of BPD
Number of subjects: 12
Study 2700321 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg ketanserin dissolved in the mouth
Number of subjects: 17
Study 2700321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 4213977 — intervention group
Group type: EXPERIMENTAL
Intervention: Empiric treatment with carbenicillin and gentamicin
Number of subjects: 0
Study 4213977 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nonabsorbable antibiotics in a prospective randomized trial
Number of subjects: 0
Study 4213977 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic carbenicillin and oral gentamicin
Number of subjects: 0
Study 30955978 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap vaccine (case group)
Number of subjects: 167
Study 30955978 — intervention group
Group type: COMPARATOR
Intervention: No vaccine (control group)
Number of subjects: 167
Study 28525305 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone)
Number of subjects: 452
Study 28525305 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP
Number of subjects: 452
Study 25264764 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-view arm
Number of subjects: 5
Study 23187956 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean protein supplement (40g, 89.3 mg isoflavones)
Number of subjects: 0
Study 23187956 — intervention group
Group type: COMPARATOR
Intervention: Milk protein supplement (40g)
Number of subjects: 0
Study 23187956 — intervention group
Group type: COMPARATOR
Intervention: Complex carbohydrate placebo (40g)
Number of subjects: 0
Study 21592351 — intervention group
Group type: EXPERIMENTAL
Intervention: GWL (Group-based behavioral weight loss program)
Number of subjects: 197
Study 21592351 — intervention group
Group type: EXPERIMENTAL
Intervention: SWA-alone (SenseWear™ Armband alone)
Number of subjects: 197
Study 21592351 — intervention group
Group type: EXPERIMENTAL
Intervention: GWL+SWA (Group-based behavioral weight loss program plus SenseWear™ Armband)
Number of subjects: 197
Study 21592351 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (self-directed weight loss program via an evidence-based weight loss manual)
Number of subjects: 197
Study 21592351 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 197
Study 21592351 — intervention group
Group type: EXPERIMENTAL
Intervention: GWL
Number of subjects: 197
Study 21592351 — intervention group
Group type: EXPERIMENTAL
Intervention: SWA-alone
Number of subjects: 197
Study 21592351 — intervention group
Group type: EXPERIMENTAL
Intervention: GWL+SWA
Number of subjects: 197
Study 19196674 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin (0.625 mg of conjugated equine estrogens plus 2.5 mg of medroxyprogesterone acetate daily)
Number of subjects: 0
Study 19196674 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16530578 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (1.0 mg/kg daily for heterozygous TPMT activity; 2.5 mg/kg daily for normal TPMT activity)
Number of subjects: 63
Study 16530578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 16530578 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 63
Study 12765849 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS stimulation (DLPFC, 15 Hz, 110% motor threshold, 3000 stimuli/day for 10 days)
Number of subjects: 25
Study 12765849 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS stimulation (midline parieto-occipital, 90% of motor threshold)
Number of subjects: 25
Study 10778915 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (IHC) for 8 weeks
Number of subjects: 20
Study 10778915 — intervention group
Group type: EXPERIMENTAL
Intervention: N‐acetylcysteine (NAC) for 8 weeks
Number of subjects: 20
Study 10778915 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term treatment with NAC
Number of subjects: 20
Study 10778915 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term treatment with IHC
Number of subjects: 20
Study 10778915 — intervention group
Group type: EXPERIMENTAL
Intervention: Sputum from COPD patients before treatment with IHC
Number of subjects: 20
Study 10778915 — intervention group
Group type: EXPERIMENTAL
Intervention: Sputum from COPD patients before treatment with NAC
Number of subjects: 20
Study 10778915 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal adhesion of unstimulated PMNs
Number of subjects: 20
Study 9489047 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic community (TC)
Number of subjects: 694
Study 9489047 — intervention group
Group type: COMPARATOR
Intervention: Community residence (CR)
Number of subjects: 694
Study 9489047 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall attrition rates
Number of subjects: 694
Study 8406147 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg twice daily) and amoxicillin suspension (500 mg four times daily) for two weeks
Number of subjects: 40
Study 8406147 — intervention group
Group type: COMPARATOR
Intervention: Bismuth subsalicylate (600 mg three times daily), metronidazole (400 mg three times daily), tetracycline (500 mg three times daily), and ranitidine (300 mg in the evening) for two weeks
Number of subjects: 40
Study 3332119 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin (CSA)
Number of subjects: 59
Study 3332119 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX)
Number of subjects: 59
Study 31236732 — intervention group
Group type: EXPERIMENTAL
Intervention: Providers with high indegree centrality
Number of subjects: 0
Study 31236732 — intervention group
Group type: EXPERIMENTAL
Intervention: Influence of providers
Number of subjects: 0
Study 31236732 — intervention group
Group type: EXPERIMENTAL
Intervention: Interviews
Number of subjects: 0
Study 29306057 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 and vitamin E co-supplementation (1000mg omega-3 fatty acids plus 400 IU vitamin E per day for 12 weeks)
Number of subjects: 40
Study 27050082 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized vestibular rehabilitation (VR)
Number of subjects: 40
Study 27050082 — intervention group
Group type: COMPARATOR
Intervention: Wait-listed control group (usual medical care)
Number of subjects: 40
Study 24911979 — intervention group
Group type: EXPERIMENTAL
Intervention: Written emotional disclosure
Number of subjects: 78
Study 24911979 — intervention group
Group type: COMPARATOR
Intervention: Control writing condition
Number of subjects: 78
Study 22344742 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam (0.5 mg/day, n = 10)
Number of subjects: 20
Study 22344742 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose, n = 10)
Number of subjects: 20
Study 22344742 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam (0.5 mg/day)
Number of subjects: 20
Study 20210263 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic medications
Number of subjects: 0
Study 20210263 — intervention group
Group type: COMPARATOR
Intervention: Brand-name medications
Number of subjects: 0
Study 18928121 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Shenmen (HT 7)
Number of subjects: 12
Study 18928121 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Yanglao (SI 6)
Number of subjects: 12
Study 15812554 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 875
Study 15812554 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiation
Number of subjects: 875
Study 15812554 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 875
Study 12139873 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk
Number of subjects: 37
Study 12139873 — intervention group
Group type: COMPARATOR
Intervention: Non-omega-6 enriched formula
Number of subjects: 37
Study 12139873 — intervention group
Group type: COMPARATOR
Intervention: Non-omega-3 formula
Number of subjects: 37
Study 10609213 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesacaine-MPF 3%
Number of subjects: 40
Study 10609213 — intervention group
Group type: COMPARATOR
Intervention: Nesacaine-MPF 2%
Number of subjects: 40
Study 10609213 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesacaine-MPF 2% and 3%
Number of subjects: 40
Study 7589632 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin acetate (3.6 mg SC depot formulation once monthly for 6 months) plus estrogen-progestogen add-back therapy (2 mg 17 beta-E2 and 1 mg norethisterone acetate once daily for 6 months)
Number of subjects: 88
Study 7589632 — intervention group
Group type: COMPARATOR
Intervention: Goserelin acetate (3.6 mg SC depot formulation once monthly for 6 months)
Number of subjects: 88
Study 1958438 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 169,369 (80 mg)
Number of subjects: 6
Study 1958438 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 169,369 (120 mg)
Number of subjects: 6
Study 1958438 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 6752042 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymopoietin pentapeptide (TP-5), treated for 6 weeks
Number of subjects: 0
Study 6752042 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment, control group
Number of subjects: 0
Study 6752042 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymopoietin pentapeptide (TP-5)
Number of subjects: 0
Study 31044748 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate (TDF) 300 mg/day
Number of subjects: 70
Study 31044748 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF) 300 mg/day plus telbivudine (LDT) 600 mg/day
Number of subjects: 70
Study 28710224 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month automated closed-loop insulin delivery combined with pump suspend feature
Number of subjects: 84
Study 28710224 — intervention group
Group type: COMPARATOR
Intervention: Sensor-augmented insulin pump therapy
Number of subjects: 84
Study 24962144 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovision correction
Number of subjects: 75
Study 24962144 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifocal intraocular lens (IOL) implantation
Number of subjects: 75
Study 24962144 — intervention group
Group type: COMPARATOR
Intervention: Both techniques (Monovision and Multifocal IOL)
Number of subjects: 75
Study 23406253 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical medications with percentage IOP reduction >22.1%
Number of subjects: 121
Study 23406253 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical medications with percentage IOP reduction
Number of subjects: 121
Study 23406253 — intervention group
Group type: EXPERIMENTAL
Intervention: Occurrence of disc haemorrhage
Number of subjects: 121
Study 21158862 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition Detectives™ program
Number of subjects: 1180
Study 19327906 — intervention group
Group type: EXPERIMENTAL
Intervention: Deodorant
Number of subjects: 84
Study 18052663 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocolized cognitive-behavioural group therapy
Number of subjects: 57
Study 18052663 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 57
Study 15821216 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchoscopic lavage
Number of subjects: 14
Study 15821216 — intervention group
Group type: COMPARATOR
Intervention: Nonbronchoscopic lavage
Number of subjects: 14
Study 11976154 — intervention group
Group type: EXPERIMENTAL
Intervention: LSE + high-intensity physical training
Number of subjects: 80
Study 11976154 — intervention group
Group type: EXPERIMENTAL
Intervention: LSE + moderate-intensity physical training
Number of subjects: 80
Study 11976154 — intervention group
Group type: COMPARATOR
Intervention: LSE + moderate-intensity physical training and LSE + high-intensity physical training (combined)
Number of subjects: 80
Study 9473913 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 25
Study 9473913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 7613144 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral doses of 0.1 ng nickel sulfate per day, following a low-nickel diet
Number of subjects: 51
Study 7613144 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral provocation tests
Number of subjects: 51
Study 7613144 — intervention group
Group type: EXPERIMENTAL
Intervention: Patch tests
Number of subjects: 51
Study 2225503 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide (Entonox)
Number of subjects: 0
Study 2225503 — intervention group
Group type: COMPARATOR
Intervention: Papaveretum
Number of subjects: 0
Study 373089 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystic fibrosis patients inhaling test aerosol
Number of subjects: 7
Study 373089 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystic fibrosis patients with terbutaline
Number of subjects: 7
Study 373089 — intervention group
Group type: COMPARATOR
Intervention: Patients with immotile-cilia syndrome
Number of subjects: 7
Study 373089 — intervention group
Group type: EXPERIMENTAL
Intervention: Coughing during clearance measurements in CF patients
Number of subjects: 7
Study 373089 — intervention group
Group type: COMPARATOR
Intervention: Discomfort from rhinitis, sinusitis, and otitis
Number of subjects: 7
Study 373089 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciliary ultrastructure in CF patients
Number of subjects: 7
Study 373089 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucociliary transport rate in CF patients
Number of subjects: 7
Study 31734699 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated EV71 vaccine (2 doses at 1 month interval)
Number of subjects: 155995
Study 31734699 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vaccination)
Number of subjects: 155995
Study 31734699 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated EV71 vaccine
Number of subjects: 155995
Study 30616740 — intervention group
Group type: EXPERIMENTAL
Intervention: GSTT1 null genotypes with exposure to mother's, father's, or parental tobacco smoke in early life
Number of subjects: 620
Study 30616740 — intervention group
Group type: EXPERIMENTAL
Intervention: GSTM1 null genotypes with exposure to father's or parental smoking
Number of subjects: 620
Study 30616740 — intervention group
Group type: EXPERIMENTAL
Intervention: GSTP1 Ile/Ile genotypes with exposure to mother's smoking
Number of subjects: 620
Study 30616740 — intervention group
Group type: COMPARATOR
Intervention: GSTP1 Val/Val or Ile/Val genotypes with exposure to mother's smoking
Number of subjects: 620
Study 28389316 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinflunine (320 mg/m2 or 280 mg/m2 every 21 days)
Number of subjects: 88
Study 28389316 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 88
Study 25527052 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic nasogallbladder drainage (ENGBD) using a 5F or 7F tube (n = 37)
Number of subjects: 73
Study 25527052 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic gallbladder stenting (EGBS) using a 7F stent (n = 36)
Number of subjects: 73
Study 23981994 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyberwand dual probe lithotriptor (Group A)
Number of subjects: 138
Study 23981994 — intervention group
Group type: COMPARATOR
Intervention: Swiss lithoclast master (Group B)
Number of subjects: 138
Study 21420121 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser acupuncture therapy performed 3 times a week for 4 weeks
Number of subjects: 91
Study 21420121 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (nonlaser light to the same points)
Number of subjects: 91
Study 21420121 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser acupuncture therapy
Number of subjects: 91
Study 18842668 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (HAL)
Number of subjects: 36
Study 18842668 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (OLZ)
Number of subjects: 36
Study 17272326 — intervention group
Group type: EXPERIMENTAL
Intervention: DDD(R)/VDD pacing
Number of subjects: 41
Study 17272326 — intervention group
Group type: COMPARATOR
Intervention: VVI(R) pacing
Number of subjects: 41
Study 17272326 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional class assessment
Number of subjects: 41
Study 17272326 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of pacemaker syndrome
Number of subjects: 41
Study 17272326 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' preferred pacing mode
Number of subjects: 41
Study 15577366 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical repair of split earlobes
Number of subjects: 25
Study 15577366 — intervention group
Group type: COMPARATOR
Intervention: Heavy gold earrings (stretched earlobes)
Number of subjects: 25
Study 15577366 — intervention group
Group type: COMPARATOR
Intervention: Gold earrings (normal earlobes)
Number of subjects: 25
Study 11605920 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl (10 microg/kg estimated fetal weight x 1.25 placental correction) given once at intrahepatic vein transfusion
Number of subjects: 16
Study 11605920 — intervention group
Group type: COMPARATOR
Intervention: Control transfusions without fentanyl
Number of subjects: 16
Study 11605920 — intervention group
Group type: COMPARATOR
Intervention: Intrahepatic vein transfusions without fentanyl
Number of subjects: 16
Study 9232713 — intervention group
Group type: EXPERIMENTAL
Intervention: Postal invitations to influenza vaccination free of charge
Number of subjects: 585
Study 9232713 — intervention group
Group type: EXPERIMENTAL
Intervention: Postal invitations to influenza vaccination on paying the usual fee (US$ 40‐60)
Number of subjects: 585